Ceftaroline Fosamil Acetate
The acetate salt form of the prodrug ceftaroline fosamil, administered intravenously to deliver active ceftaroline for the treatment of serious infections including MRSA. It provides fifth-generation cephalosporin coverage with unique MRSA activity. Renal dose adjustment is required in patients with moderate to severe kidney impairment.
Peso Molecular
744,7000 g/mol
TPSA
368,00 Ų
Mecanismo de Ação
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)O.CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1.O
InChI
InChI=1S/C22H21N8O8PS4.C2H4O2.H2O/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10;1-2(3)4;/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37);1H3,(H,3,4);1H2/b26-13-;;/t14-,19-;;/m1../s1
Molecular Formula
C24H25N8O10PS4
HBD / HBA
5 / 19
Ligações Rotacionáveis
11
Átomos Pesados
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The acetate salt form of the prodrug ceftaroline fosamil, administered intravenously to deliver active ceftaroline for the treatment of serious infections including MRSA. It provides fifth-generation cephalosporin coverage with unique MRSA activity. Renal dose adjustment is required in patients with moderate to severe kidney impairment.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceftaroline Fosamil Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3544973. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 56841980. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftaroline-fosamil-acetate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftaroline-fosamil-acetate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftaroline-fosamil-acetate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftaroline-fosamil-acetate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftaroline-fosamil-acetate"></drugfyi-drug>